Cacciola I, Borgia F, Filomia R, et al. - Researchers examined how anti-hepatitis C virus (HCV) direct-acting antiviral (DAA) treatment affects cutaneous psoriasis. An expert dermatologist evaluated skin lesions in 37 consecutive HCV patients with cutaneous psoriasis who underwent efficacious DAA treatment and were efficiently cured as shown by HCV RNA negativity 24 weeks after stopping therapy (PT24W). He used the psoriasis area severity index (PASI) scoring system to perform evaluation at baseline, end of treatment (EOT), and at PT24W. Stable disease was reported in six patients throughout the study period, whereas a significant improvement of the skin lesions at EOT was reported in 31/37 patients (83.8%). However, compared with EOT, a dramatic worsening of the psoriatic lesions at PT24W was noted in 24 of these 31 patients (77.4%), with lesion severity comparable to baseline. Baseline PASI score, age, gender, HCV genotype, liver disease stage as well as of the presence of arterial hypertension, diabetes, and autoimmune diseases were noted to have no influence on the outcome of psoriasis during and after treatment. These findings suggest only a transient effect of DAA-based HCV cure on skin lesions of patients with concomitant cutaneous psoriasis.